Balyasny Asset Management
AIMT

Balyasny Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Balyasny Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-388,384
Closed -$13.4M – 1879
2020
Q3 		$13.4M Buy
388,384
+153,529
+65% +$3.27M 0.1% 306
2020
Q2 		$3.92M Sell
234,855
-174,721
-43% -$2.97M 0.03% 580
2020
Q1 		$5.91M Buy
409,576
+196,274
+92% +$5.02M 0.07% 365
2019
Q4 		$7.14M Sell
213,302
-460,465
-68% -$12.9M 0.04% 513
2019
Q3 		$14.1M Buy
673,767
+508,089
+307% +$10.4M 0.1% 312
2019
Q2 		$3.45M Buy
165,678
+133,765
+419% +$2.75M 0.02% 717
2019
Q1 		$713K Sell
31,913
-344,846
-92% -$8.12M ﹤0.01% 1104
2018
Q4 		$9.01M Sell
376,759
-26,280
-7% -$680K 0.07% 375
2018
Q3 		$11M Buy
403,039
+38,227
+10% +$1.08M 0.05% 458
2018
Q2 		$9.81M Sell
364,812
-352,063
-49% -$10.8M 0.04% 493
2018
Q1 		$22.8M Buy
+716,875
New +$25.2M 0.1% 299

Balyasny Asset Management's AIMT Position: Q4 2020 in Review

Balyasny Asset Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 388,384 shares — an estimated $13.4M sold.

Balyasny Asset Management first reported a position in AIMT in Q1 2018 and held it in 11 quarters. The position peaked at $22.8M in Q1 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Balyasny Asset Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Balyasny Asset Management sold 388,384 Aimmune Therapeutics shares in Q4 2020, an estimated $13.4M.
  • Balyasny Asset Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 11 quarters.
  • Balyasny Asset Management's Aimmune Therapeutics position peaked at $22.8M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Balyasny Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.